Artemisinin induces hormonal imbalance and oxidative damage in the erythrocytes and uterus but not in the ovary of rats

Abstract

Artemisinin is an antimalarial drug previously reported to induce neurotoxicity and embryotoxicity in animal models. This study investigated the erythrocytes and reproductive toxicity potentials of artemisinin in female rats. Animals were randomly divided into four study groups of eight rats each. The control group (group I) received corn oil, the vehicle, while groups II–IV were orally exposed to 7, 35 and 70 mg kg⁻¹ day⁻¹ of artemisinin, respectively, by gastric intubation for 7 consecutive days. Subsequently, we evaluated the impact of artemisinin on the endocrine environment and selected markers of oxidative damage and antioxidant status of the erythrocytes, ovary and uterus. Artemisinin significantly increased hydrogen peroxide (H₂O₂) and malondialdehyde (MDA) levels and decreased catalase, glutathione peroxidase and superoxide dismutase activities in erythrocytes and uterus of rats compared with control group (p < 0.05). However, artemisinin did not alter ovarian MDA, H₂O₂, glutathione levels and catalase activity, while ovarian and uterine histological assessment revealed absence of visible lesions. Moreover, artemisinin significantly decreased follicle-stimulating hormone and increased progesterone levels compared with control (p < 0.05). Thus, these data suggest that in the absence of malarial parasite infection, artemisinin induced hormonal imbalance and oxidative damage in the erythrocytes and uterus but spared the ovary of rats.

Keywords

Artemisinin antimalarial drug abuse hormonal imbalance uterine oxidative damage erythrocytes

Introduction

Malaria is one of the world’s leading infectious killer diseases,¹ which results in the death of about 2 million people yearly. Therefore, researchers have employed several efforts to “roll back malaria” in order to prevent/eradicate the disease. In spite of this, the disease still affects about 3 billion people in 109 countries including several African regions.² Malaria is caused by four species of intracellular protozoans of the genus Plasmodium. ³ Among these species, Plasmodium falciparum is the most deadly and widespread. It produces certain proteins that move to the surface of infected red blood cells (RBCs), in order to be adhered to the vascular endothelium, thereby evading spleen clearance.⁴ Indeed, the scourge of malaria is attributed to the emergence of drug-resistant parasites.⁵ Artemisinin and its derivatives are active and effective antimalarials against multiresistant strains of Plasmodium falciparum. Artemisinin is an endoperoxide sesquiterpene lactone isolated from the aerial parts of Artemisia annua.^6,7

The antimalarial mechanism of action of artemisinin is due to the presence of the endoperoxide bridge (Figure 1). In this case, C-centered free radicals^2,8 are generated as a consequence of Fe²⁺-induced cleavage of the peroxide bond. In addition, peroxides are a known source of reactive oxygen species (ROS) such as hydroxyl and superoxide radicals,⁹ which can cause damage to tissues. For instance, several studies have reported that the treatment of membranes (in the presence of haeme) with artemisinin caused lipid peroxidation (LPO), a consequence of free radical damage.^10,11 In spite of the in utero toxicities of artemisinin and its derivatives reported in animal models,^12

–15 studies that focused on erythrocytes and the reproductive toxicities of artemisinin prior to pregnancy in the absence of malarial parasite infection are scarce.

Figure 1.

Chemical structure of artemisinin.²

Oxidative stress affects erythrocytes largely due to the presence of high concentration of cellular oxygen, haemoglobin and polyunsaturated fatty acids in their membrane. Consequently, antioxidants scavenge ROS in order to maintain the integrity of the RBCs membrane.¹⁶ Considering the facts that artemisinin-induced reduction in reticulocytes is more pronounced in healthy volunteers than in malarial patients,¹⁷ and the artemisinin-induced ROS production, this study was carried out to investigate the erythrocyte antioxidant response to artemisinin exposure in the rats.

Further, the artemisinin-induced generation of ROS can exacerbate ROS production in reproductive tissues above the normal physiological range, if the antioxidative systems fail to curtail the ROS generated.¹⁸ This increased ROS production can consequently result in the modification of susceptible molecules including DNA, lipids and proteins in these tissues due to oxidative stress. In addition to this, the reported neurotoxic effects of artemisinin and its derivatives in different animal models^19
–21 have generated issues of concern lately. In this case, exposure to neurotoxic agents such as artemisinin can cause dysfunction of the female reproductive system because of the hypothalamic–pituitary–gonadal axis connection.²² Thus, due to the reported artemisinin-induced neurotoxicity and ROS production in animal models, we also assessed the impact of artemisinin on the levels of reproductive hormones as well as ovarian and uterine ROS-antioxidants relationship in the rats.

Materials and methods

Drugs and chemicals

Artemisinin (98%) (Sigma Chemical Co., Missouri, USA) was provided through the courtesy of Molecular Bio/Sciences Limited (Calabar, Nigeria). Epinephrine, glutathione (GSH), 5′,5′-dithio-bis-2-nitrobenzoic acid, hydrogen peroxide (H₂O₂), thiobarbituric acid (TBA) and 1-chloro-2,4-dinitrobenzene (CDNB) were also purchased from Sigma Chemical Co.. All other reagents were of analytical grade and were obtained from the British Drug House (Poole, Dorset, UK).

Experimental design

Adult female albino Wistar rats (age about 3 months; weight 150–220 g) obtained from the Central Animal House Facility, College of Medicine, University of Ibadan, Nigeria, were used in the present study. Acclimatization of animals and treatment were carried out in a ventilated room. They were placed in plastic cages and kept under controlled conditions of natural photoperiod of about 12-h light–dark cycle daily and allowed free access to water and standard rat pellet chow diet. This study was approved by the Institutional Ethical Committee and carried out in accordance with the guidelines of the National Institute of Health for laboratory animal care and use.²³ After 1 week of acclimatization, the rats were randomly divided into four groups of eight rats each. Different doses of artemisinin (7–70 mg kg⁻¹ day⁻¹) were administered for 7 consecutive days to the different groups of rats based on the recommendation for artemisinin monotherapy regimen.²⁴ Rats in group I, the control group, received corn oil alone. Groups II–IV rats received 7, 35 and 70 mg kg⁻¹ of artemisinin, respectively, and weighed before and after exposure to artemisinin. We used artemisinin as a prototype of other antimalarials in the same class, because unlike others, it is not metabolised to dihydroartemisinin.²⁵ The 7 mg kg⁻¹ day⁻¹ dose was selected based on the therapeutic dose of artemisinin in adult humans (500 mg day⁻¹).^26,27 The 35 and 70 mg kg⁻¹ doses represent 5 and 10 times the therapeutic dose of artemisinin, respectively, and they are still low when compared with the lethal dose 50 that is greater than 5000 mg kg⁻¹.²⁸ In this study, we attempt to simulate a situation in which artemisinin is used in a non-pregnant state without malarial parasite infection. This is common in environments where drug abuse is a common practice.

Blood and organ collection

At the end of the experimental period, animals were fasted overnight and killed by cervical dislocation. Blood was collected by cardiac puncture into anticoagulant bottles and centrifuged at 3000g at room temperature for 15 min to obtain the plasma used for hormonal analysis. The ovaries and uteri were quickly removed, washed in cold 1.15% potassium chloride (KCl), weighed and homogenized in 50 mM of Tris-hydrochloric acid buffer (pH 7.4) containing 1.15% KCl and centrifuged at 10,000g for 10 min to obtain the post-mitochondrial supernatant fractions used for biochemical assays. In addition, samples from the ovaries and uteri were fixed in Bouin’s fixative for histopathological examination.

Preparation of erythrocytes

After the separation of plasma from the blood obtained above, the erythrocytes were washed three times with ice cold phosphate-buffered saline (PBS: 145 mM sodium chloride (NaCl), 1.9 mM monosodium phosphate (NaH₂PO₄) and 8.1 mM disodium phosphate (Na₂HPO₄), pH 7.4) and centrifuged at 3000g for 10 min. The erythrocyte pellets obtained were thereafter resuspended in PBS (NaCl, NaH₂PO₄, 0.1 M Na₂HPO₄, pH 7.4) at 1:9 dilutions and used for the evaluation of erythrocyte biochemical assays.

Biochemical investigations

Protein concentration

The method of Lowry et al.²⁹ was used to determine protein concentration in the samples.

Determination of LPO

LPO was assayed as malondialdehyde (MDA) using the method of Farombi et al.³⁰ and Buege and Aust.³¹ Aliquot of 0.4 mL sample was mixed with 1.6 mL of Tris-KCl buffer after which 0.5 mL of 30% trichloroacetic acid (TCA) was added. Subsequently, 0.5 mL of 0.75% TBA was added and incubated for 45 min at 80°C. After cooling in ice, the mixture was centrifuged at 3000g. The absorbance of the clear supernatant was read against a reference blank at 532 nm. Lipid peroxidation in units per milligram of protein was thereafter computed using a molar extinction coefficient of 1.56 × 10⁵ m⁻¹ cm⁻¹.

H₂O₂ generation assay

H₂O₂ generation was assayed by the method of Wolff³² and expressed as micromole per milligram of protein.

Determination of superoxide dismutase activity

The superoxide dismutase (SOD) activity was determined by the method of Misra and Fridovich.³³ Briefly, 200 μL of the sample and 2.5 mL of 0.05 M carbonate buffer (pH 10.2) were equilibrated in the spectrophotometer. The reaction was allowed to commence by adding 300 µL of freshly prepared 0.3 mM adrenaline to the mixture mixed by inversion. Increase in absorbance at 480 nm was monitored every 30 s for 150 s. The specific activity of SOD is expressed as unit per milligram of protein.

Determination of catalase activity

Catalase activity was assayed using the method of Clairborne.³⁴ Briefly, the assay mixture contains 2.40 mL of phosphate buffer (50 mM, pH 7.0), 10 μL of 19 mM of H₂O₂ and 50 μL of sample allowed to run for 3 min at 30-s interval and thereafter terminated by the addition of 2 mL of dichromate/acetic acid solution, followed by heating for 10 min in a boiling water bath. After cooling the mixture at room temperature, decreases in absorbance was read with a spectrophotometer at 570 nm. Values are expressed as micromole of H₂O₂ consumed per minute per milligram of protein.

Determination of glutathione-S-transferase activity

The glutathione-S-transferase (GST) activity was determined by the method of Habig et al.³⁵ Briefly, the reaction mixture of 1.7 mL of 100 mmol L⁻¹ of phosphate buffer (pH 6.5) and 0.1 mL of 30 mmol L⁻¹ of CDNB was pre-incubated for 5 min at 37°C followed by the addition of 20 μL of the sample. The absorbance of the reaction mixture was monitored for 5 min at 340 nm against the blank. The specific activity of GST is expressed as micromole per minute per milligram of protein using an extinction coefficient of 9.6 mm⁻¹ cm⁻¹.

Determination of glutathione peroxidase activity

The method of Rotruck et al.³⁶ was used to determine glutathione peroxidase (GPx) activity. Briefly, the assay mixture of 500 μL of sodium phosphate buffer, 100 μL of 10.0 mM of sodium azide, 200 μL of 4.0 mM of GSH, 100 μL of 2.5 mM of H₂O₂ and 50 μL of the sample was made up to 2.0 mL with distilled water, incubated at 37°C for 3 min, and terminated by adding 0.5 mL of 10% TCA. The supernatant obtained after centrifugation was used to determine residual GSH content by the addition of 4.0 mL of 0.3 M disodium hydrogen phosphate solution and 1 mL of DTNB reagent. The absorbance was read in a spectrophotometer at 412 nm against a reagent blank.

Determination of reduced GSH

The GSH was determined using the method of Jollow et al.³⁷ Briefly, an aliquot of the sample was deproteinized by the addition of an equal volume of 4% sulfosalicylic acid and centrifuged at 10,000g for 15 min at 4°C. The supernatant (50 μL) was then added to 4.5 mL of DTNB and the absorbance read at 412 nm.

Determination of plasma follicle-stimulating hormone, prolactin, progesterone and estrogen concentrations

We evaluated luteinising hormone, follicle-stimulating hormone (FSH), prolactin, progesterone and estrogen concentrations using commercial enzyme immunoassay kits specific for rats according to the manufacturers’ procedures. Luteinising hormone and FSH kits were obtained from Amersham, UK. Prolactin and progesterone kits were obtained from Cayman Chemical (USA), while estrogen kit was obtained from MyBioSource Inc. (USA).

Histological evaluation

The ovary and uterus specimens were fixed in Bouin’s solution, dehydrated in ethanol, cleared in xylene and embedded in parafin. Sections of 4–5 µm were cut using a microtome and stained with hematoxylin and eosin stain. The slides were examined under a light microscope by investigators blinded to control and artemisinin-treated groups.³⁸

Statistical analysis

The results are expressed as Mean ± SD (standard deviation). Statistical analysis was performed using a one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. The results were considered statistically significant at p < 0.05.

Results

Body and reproductive organ weights of female rats treated orally with 7, 35 and 70 mg kg⁻¹ of artemisinin for 7 days

As shown in Table 1, expected weight gains occurred in the control and artemisinin-exposed rats. However, artemisinin caused dose-dependent significant decreases in percentage of body weight changes across the treated groups compared with the control (p < 0.05). In addition, artemisinin significantly increased ovarian weights compared with the control group (p < 0.05).

Table 1.

Body and reproductive organ weights of female Wistar rats treated orally with 7, 35 and 70 mg kg⁻¹ of artemisinin for 7 days.

Parameters	Control group	Artemisinin 7 mg kg⁻¹	Artemisinin 35 mg kg⁻¹	Artemisinin 70 mg kg⁻¹
Initial weights (g)	152.50 ± 10.35	152.50 ± 14.88	152.50 ± 18.32	152.50 ± 18.32
Final weights (g)	187.50 ± 10.35	177.50 ± 12.82	168.75 ± 21.00	166.25 ± 17.68
Change in body weights (%)	22.95	16.39*	10.66*	9.02*
Ovary (g)	0.04 ± 0.01	0.11 ± 0.03*	0.10 ± 0.02*	0.10 ± 0.01*
Uterus (g)	0.30 ± 0.02	0.23 ± 0.03	0.26 ± 0.03	0.23 ± 0.03

The results are presented as mean ± standard deviation of eight animals. Significant difference compared with control, *p < 0.05.

Effects of artemisinin on oxidative stress markers of female rats treated orally with 7, 35 and 70 mg kg⁻¹ of artemisinin for 7 days

The effects of artemisinin on oxidative stress markers MDA and H₂O₂ after 7 days of oral exposure of female rats to artemisinin are depicted in Figures 2 and 3, respectively. Artemisinin did not alter ovarian MDA and H₂O₂ levels but caused significant dose-dependent elevations in uterine and erythrocyte MDA (p < 0.05) levels in the 35 and 70 mg kg⁻¹ artemisinin groups compared with control (Figure 2). In addition, uterine H₂O₂ generation significantly increased in all the artemisinin-treated groups, while erythrocyte H₂O₂ generation significantly increased in the 35 and 70 mg kg⁻¹ artemisinin groups compared with control (Figure 3).

Figure 2.

Ovarian, uterine, and erythrocyte LPO status of female rats treated with 7, 35 and 70 mg kg⁻¹ of artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control, *p < 0.05.

Figure 3.

Ovarian, uterine, and erythrocyte H₂O₂ generated in female rats treated with 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control, *p < 0.05.

Ovarian, uterine and erythrocyte antioxidant levels of female rats exposed to artemisinin

The levels of antioxidant markers after 7 days of oral exposure of female rats to 7, 35 and 70 mg kg⁻¹ artemisinin are shown in Figures 4 to 8. In the artemisinin-treated groups, there were significant reductions in the activities of uterine and erythrocyte SOD (Figure 4), catalase (Figure 5), and GPx (Figure 7) when compared with the control values (p < 0.05). The ovarian catalase activity (Figure 5) and GSH level (Figure 8) were not altered in the rats after 7 days’ treatment with artemisinin. The data also reflect significant increases in the activities of ovarian and erythrocyte GST in the 35 and 70 mg kg⁻¹ artemisinin groups compared with control (Figure 6). Moreover, 7 days oral exposure of female rats to 7, 35, and 70 mg kg⁻¹ artemisinin significantly decreased uterine GST activity (Figure 6) and GSH levels (Figure 8) when compared with the control group, while erythrocyte GSH levels (Figure 8) decreased in the 35 and 70 mg kg⁻¹ artemisinin groups compared with control (p < 0.05).

Figure 4.

Ovarian, uterine, and erythrocyte superoxide dismutase activity of female rats treated with 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control, *p < 0.05.

Figure 5.

Ovarian, uterine, and erythrocyte catalase activity of female rats treated with 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control, *p < 0.05.

Figure 6.

Ovarian, uterine, and erythrocyte glutathione-S-transferase activity of female rats treated with 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control, *p < 0.05.

Figure 7.

Ovarian, uterine, and erythrocyte glutathione peroxidase activity of female rats treated with 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control, *p < 0.05.

Figure 8.

Ovarian, uterine, and erythrocyte reduced glutathione levels in female rats treated with 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control group, *p < 0.05.

Plasma reproductive hormonal levels of female rats treated with artemisinin for 7 days

Figure 9(a)-(e) shows the effects of artemisinin on reproductive hormonal levels in female rats. Artemisinin did not alter the level of LH in the treated groups (Figure 9(a)) but significantly reduced FSH (Figure 9(b)), and increased progesterone levels in the artemisinin-exposed rats (Figure 9(d)) compared with the control (p < 0.05). In addition, artemisinin caused non-significant increases in prolactin (Figure 9(c)) and estrogen (Figure 9(e)) levels compared with the control.

Figure 9.

Levels of (a) luteinizing hormone, (b) follicle-stimulating hormone, (c) prolactin, (d) progesterone and (e) estrogen in female rats treated with 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. The results are presented as mean ± standard deviation of 8 animals. Significant difference compared with control, *p < 0.05.

Ovarian and uterine histology after exposure of female rats to artemisinin

Figure 10 shows the representative photomicrographs of ovarian and uterine sections after exposure of female rats to 7, 35 and 70 mg kg⁻¹ artemisinin for 7 days. Artemisinin did not appear to cause any noticeable lesion in the ovarian and the uterine architecture under light microscopic examination.

Figure 10.

Representative photomicrographs of haematoxylin–eosin-stained ovarian and uterine sections from control and artemisinin-treated rats after 7 days of exposure (×400). A1-D1 reflect ovary of control (A1) and artemisinin-treated rats administered with 7, 35 and 70 mg kg⁻¹ artemisinin (B1, C1 and D1), respectively: No visible lesions were seen. A2-D2 reflect uterus of control (A2) and artemisinin-treated rats exposed to 7, 35 and 70 mg kg⁻¹ artemisinin (B2, C2 and D2), respectively. No visible lesions were seen.

Discussion

In malaria-endemic regions of tropical Africa, the treatment of malaria is usually based on fever, rather than the confirmation of parasitemia.^39,40 This is because several other diseases have symptoms similar to malaria.⁴¹ In the present study, we investigated the toxicity potential of artemisinin in erythrocytes, ovary and uterus of rats in the absence of pregnancy and malarial parasite infection. Our data demonstrated that artemisinin induced oxidative stress in the uterus and erythrocytes and disrupted hormonal balance in rats.

Oxidative stress has been implicated in the aetiology of reproductive and erythrocytic diseases.⁴² In our study, the artemisinin-induced uterine and erythrocyte increases in MDA and H₂O₂ generation, suggest the induction of oxidative stress in these tissues. H₂O₂ has been reported to induce the peroxidation of polyunsaturated fatty acid to yield highly reactive MDA.^43,44 Thus, LPO can induce injury to tissues by altering the physicochemical properties of membrane lipid bilayers, leading to severe cellular dysfunction.⁴⁵ Our data corroborate several reports in which antimalarial drugs such as amodiaquine,⁴⁶ mefloquine and halofantrine,⁴⁷ artesunate,⁴⁸ artemether-lumefantrine,^49,50 artesunate-amodiaquine,⁵¹ and artemisinin⁵² caused elevated levels of MDA and/or H₂O₂ in different tissues. However, the current study showed that artemisinin did not cause elevation in ovarian MDA and H₂O₂.

Further, the artemisinin-induced LPO in the uterus and erythrocytes may be due to decreased activities of SOD and catalase as observed in this study. This is because SOD is the first line of defence enzyme against the deleterious effects of oxyradicals (O₂ ⁻), which causes damage to uterine and erythrocyte membrane structures. Indeed, catalase serves an important role in the ovary, uterus, and erythrocytes by scavenging H₂O₂ at high concentration, thereby converting it to water and molecular oxygen. Indeed, a decrease in SOD activity has been linked with increased O₂ ⁻ and decreased catalase activity as observed in this study.⁴⁴ In conjunction with catalase, GPx scavenges H₂O₂ in order to protect uterine and erythrocyte membranes from LPO. If GPx fails to eliminate H₂O₂ from the cell, H₂O₂ accumulates leading to a reduction in SOD activity.⁵³ In contrast, the observed increases in ovarian GPx and catalase activities suggest an adaptive response that helps to protect the ovary from the toxicity of artemisinin and/or its metabolites.

The depletions in uterine and erythrocyte GSH as observed in this study, further confirm induction of oxidative damage in these tissues. GSH is essential in the detoxification of free radicals in the erythrocyte and female reproductive tissues by binding with the products of LPO and other toxic endogenous substances. In addition, our data indicated depletion in uterine GST activity after artemisinin exposure in the rats. As a phase II metabolising enzyme, GST conjugates with xenobiotics, thus increasing their polarity, in order to neutralize and eliminate them from the system.⁵⁴ The reduction in uterine GST activity in this study, therefore, may suggest impaired detoxification of artemisinin and/or its metabolites, which further implies uterine oxidative damage.

The endometrium is a tissue where considerable angiogenesis occurs on a regular physiological basis.⁵⁵ Oxidative stress in the uterus, as shown in the present study, is one of the possible causes of recurrent implantation failure and repeated miscarriages. For instance, elevated H₂O₂ has been linked with the disruption of uterine movement and homeostasis via several mechanisms.⁵⁶ Although this study reflected induction of oxidative stress in the uterus, histopathological examination under light microscope showed no significant damage to uterine and ovarian sections after the 7-day period of artemisinin exposure in rats.

The hormonal imbalance observed in this study is possibly due to the reported neurotoxic effect of artemisinin,^19
–21 since the female reproductive axis is regulated by the communication among the hypothalamus, pituitary, and the ovary.^57,58 The observed dose-dependent increase in progesterone level in all the artemisinin-treated rats may lead to a disruption in ovulation process. Indeed, progesterone inhibits the action of FSH, thereby preventing the development of new follicles and eggs.⁵⁹ This increase in progesterone concentrations in the rats might have elicited a negative feedback mechanism in the pituitary gonadotropin, FSH, thereby causing significant reduction in its level in the rats.

In conclusion, our data indicated that artemisinin-induced mechanism of uterine and erythrocyte toxicities seems to be associated with the induction of oxidative stress in these tissues. Furthermore, the disruption of hormonal balance caused by artemisinin exposure in the rats may perturb ovulation process. Considering these possible risks associated with artemisinin misuse, we, therefore, advice that confirmation of parasitemia should be ensured before the drug is taken.

Footnotes

Acknowledgement

The authors are grateful to Professor Brisibe Andi of the Molecular Biosciences Ltd, 124 MCC Road, Calabar, Cross River State, Nigeria for the generous gift of the artemisinin used in this study.

Conflict of Interest

The authors declared no conflicts of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

World Health Organisation. World Malaria Report. Geneva, Switzerland: WHO, 2012.

O’Neill

Barton

Ward

. The molecular mechanism of action of artemisinin-the debate continues. Molecules 2010; 15: 1705–1721.

Snow

Trappe

Marsh

. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol 2005; 17: 593–597.

Clark

. Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients. Birth Defects Res A 2012; 94: 61–75.

Taylor

White

. Antimalarial drug toxicity: a review. Drug Saf 2004; 27: 25–61.

Ying

. Qinghaosu (artemisinin): chemistry and pharmacology. Acta Pharmacol Sin 2012; 33: 1141–1146.

Blazquez

Fernandez-Dolona

Sanchez-Vicentea

. Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorg Med Chem 2013; 21: 4432–4441.

Shi

Zhang

. Hemopoietotoxicity in pregnant mice and their embryos induced by free radicals derived from sodium artesunate. Chin J Pharmacol Toxicol 1997; 11: 226–228. Chinese.

Halliwell

Gutteridge

JMC

. Free radicals in biology and medicine. 3rd ed. Oxford, UK: Clarendon Press, 1999.

10.

Berman

Adams

. Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radic Biol Med 1997; 22(7): 1283–1288.

11.

Meshnick

. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32(13): 1655–1660.

12.

Longo

Zanoncelli

Della Torre

. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin [DHA] on rat embryos. Reprod Toxicol 2006; 22(4): 797–810.

13.

Alkadi

. Antimalarial drug toxicity: a review. Chemotherapy 2007; 53: 385–391.

14.

Boareto

Juliane

Aedra

. Toxicity of artemisinin (Artemisia annua L.) in two different periods of pregnancy in wistar rats. Reprod Toxicol 2008; 25: 239–246.

15.

El-Dakdoky

. Evaluation of the developmental toxicity of artemether during different phases of rat pregnancy. Food Chem Toxicol 2009; 47: 437–441.

16.

Eritsland

. Safety considerations of polyunsaturated fatty acids. Am J Clin Nutr 2000; 71(1): 197–201.

17.

Price

van Vugt

Phaipun

. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60: 547–555.

18.

Fujii

Iuchi

Okada

. Fundamental roles of reactive oxygen species and protective mechanisms in the female reproductive system. Reprod Biol Endocrin 2005; 3: 43.

19.

Brewer

Grate

Peggins

. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994; 51: 251–259.

20.

Wesche

DeCoster

Tortella

. Neurotoxicity of artemisinin analogs in vitro. Antimicrob Agents Chemother 1994; 38: 1813–1819.

21.

Schmuck

Roehrdanz

Haynes

. Neurotoxic mode of action of artemisinin. Antimicrob Agents Chemother 2002; 46: 821–827.

22.

Gray

Jr . Delayed effects on reproduction following exposure to toxic chemicals during periods of development. In: Cooper

Goldman

Harbin

(eds) Aging and environmental toxicology: biological and behavioral perspectives. Baltimore, MD: The Johns Hopkins University Press, 1991, p. 183.

23.

PHC. Public health service policy on humane care and use of laboratory animals. Washington, DC: US Department of Health and Human Services, 1996, pp. 99–158.

24.

Adjuik

Babiker

Garner

. International artemisinin study group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363: 9–17.

25.

Woodrow

Haynes

Krishna

. Artemisinins. Post Grad Med J 2004; 81: 71–78.

26.

Hung

Vries

Thuy

. Single dose artemisinin-mefloquine versus mefloquine alone uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91: 191–194.

27.

Ashton

Nguven

. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 1998; 63(4): 482–493.

28.

Agtmael

Eggelte

van Boxtel

. Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci 1999; 20(5): 199–205.

29.

Lowry

Rosenbrough

Farr

. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265–275.

30.

Farombi

Tahnteng

Agboola

. Chemoprevention 2-acetylaminofluorene-induced hepatotoxicity and lipid peroxidation in rats by kolaviron-a Garcinia kola seed extract. Food Chem Toxicol 2000; 38: 535–541.

31.

Buege

Aust

. Microsomal lipid peroxidation. Method Enzymol 1978; 30: 302–310.

32.

Wolff

. Ferrous ion oxidation in the presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Meth Enzymol 1994; 233: 182–189.

33.

Misra

Fridovich

. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170–3175.

34.

Clairborne

. Catalase activity. In: Greewald

(ed) Handbook of methods for oxygen radical research. Boca Raton, FL: CRC, 1995, pp. 237–242.

35.

Habig

Pabst

Jakoby

. Glutathione-S-transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130–7139.

36.

Rotruck

Pope

Ganther

. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588–590.

37.

Jollow

Mitchell

Zampaglione

. Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3, 4 bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 1974; 11: 151–169.

38.

Drury

Wallington

. Carleton’s histological technique. 4th ed. New York, NY: Oxford University Press, 1967, pp. 114–123.

39.

WHO—World Health Organization. Assessment of the safety of artemisinin compounds in pregnancy. Geneva, Switzerland: WHO, 2003.

40.

WHO—World Health Organisation. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland: WHO, 2010.

41.

Msellem

Martensson

Rotllant

. Influence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validation Study. PLOS Medicine 2009; 6(4): e1000070.

42.

Pejic

Todorovic

Stojiljkovic

. Antioxidant enzymes and lipid peroxidation in endometrium of patients with polyps, myoma, hyperplasia and adenocarcinoma. Reprod Biol Endocrin 2009; 7: 149.

43.

Marnett

. Lipid peroxidation—DNA damage by malondialdehyde. Mut Res Fund Mol Mech Mutagen 1999; 424: 83–95.

44.

Samuel

Stanley

Roopha

. Lactional hexavalent chromium exposure-induced oxidative stress in rat uterus is associated with delayed puberty and impaired gonadotropin levels. Hum Exp Toxicol 2011; 30(2): 91–101.

45.

Catala

. Lipid peroxidation. In: Pantopoulos

Schipper

(eds) Principles of free radical biomedicine. vol. 1, chapter 7. New York, NY: McGill University, Nova Science, 2011, pp. 137–160.

46.

Farombi

. Influence of amodiaquine treatment on microsomal lipid peroxidation and antioxidant defense systems of rats. Pharmacol Toxicol 2000; 87: 249–254.

47.

Farombi

Olowu

Emerole

. Effect of three structurally related antimalarial drugs on liver microsomal components and lipid peroxidation in rats. Comp Biochem Physiol 2000; 126: 217–224.

48.

Adebayo

Igunnu

Arise

. Effects of co-administration of artesunate and amodiaquine on some cardiovascular disease indices in rats. Food Chem Toxicol 2011; 49: 45–48.

49.

Adaramoye

Osaimoje

Akinsanya

. Changes in antioxidant status and biochemical indices after acute administration of artemether, artemether-lumefantrine and halofantrine in rats. Basic Clin Pharmacol Toxicol 2008; 102: 412–418.

50.

Abolaji

Eteng

Omonua

. Influence of co-administration of artemether and lumefantrine on selected plasma biochemical and erythrocyte oxidative stress indices in female Wistar rats. Hum Exp Toxicol 2013; 32(2): 206–215.

51.

Abolaji

Osedeme

Olusemire

. Artesunate-amodiaquine combination therapy in the absence of malarial parasite infection induces oxidative damage in female rats. Cell Biochem Funct. Epub ahead of print 3 December 2013; doi:10.1002/cbf.3020.

52.

Farombi

Adedara

Abolaji

. Sperm characteristics, antioxidant status and hormonal profile in rats treated with artemisinin. Andrologia. Epub ahead of print 30 September 2013. doi:10.1111/and.12170.

53.

Sen

. Nutritional biochemistry of cellular glutathione. J Nutr Biochem 1997; 8: 660–672.

54.

Hayes

Strange

. Potential contribution of the glutathione-S-transferase supergene family to resistance to oxidative stress. Free Radic Res 1995; 22: 193–207.

55.

Girling

Rogers

. Recent advances in endometrial angiogenesis research. Angiogenesis 2005; 8: 89–99.

56.

Appiah

Milovanovic

Radojicic

. Hydrogen peroxide affects contractile activity and anti-oxidant enzymes in rat uterus. Br J Pharmacol 2009; 158: 1932–1941.

57.

Bates

Bowling

. Physiology of the female reproductive axis. Periodontology 2000 2013; 61: 89–102.

58.

Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404–2411.

59.

Nippoldt

Reame

Kelch

. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 1989; 69: 67–76.

Artemisinin induces hormonal imbalance and oxidative damage in the erythrocytes and uterus but not in the ovary of rats

Abstract

Keywords

Introduction

Materials and methods

Drugs and chemicals

Experimental design

Blood and organ collection

Preparation of erythrocytes

Biochemical investigations

Protein concentration

Determination of LPO

H2O2 generation assay

Determination of superoxide dismutase activity

Determination of catalase activity

Determination of glutathione-S-transferase activity

Determination of glutathione peroxidase activity

Determination of reduced GSH

Determination of plasma follicle-stimulating hormone, prolactin, progesterone and estrogen concentrations

Histological evaluation

Statistical analysis

Results

Body and reproductive organ weights of female rats treated orally with 7, 35 and 70 mg kg−1 of artemisinin for 7 days

Effects of artemisinin on oxidative stress markers of female rats treated orally with 7, 35 and 70 mg kg−1 of artemisinin for 7 days

Ovarian, uterine and erythrocyte antioxidant levels of female rats exposed to artemisinin

Plasma reproductive hormonal levels of female rats treated with artemisinin for 7 days

Ovarian and uterine histology after exposure of female rats to artemisinin

Discussion

Footnotes

Acknowledgement

Conflict of Interest

Funding

References

H₂O₂ generation assay

Body and reproductive organ weights of female rats treated orally with 7, 35 and 70 mg kg⁻¹ of artemisinin for 7 days

Effects of artemisinin on oxidative stress markers of female rats treated orally with 7, 35 and 70 mg kg⁻¹ of artemisinin for 7 days